Hypertriglyceridemia: a potential side effect of propofol sedation in critical illness View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-09-28

AUTHORS

J.-C. Devaud, M. M. Berger, A. Pannatier, P. Marques-Vidal, L. Tappy, N. Rodondi, R. Chiolero, P. Voirol

ABSTRACT

PurposeHypertriglyceridemia (hyperTG) is common among intensive care unit (ICU) patients, but knowledge about hyperTG risk factors is scarce. The present study aims to identify risk factors favoring its development in patients requiring prolonged ICU treatment.MethodsProspective observational study in the medicosurgical ICU of a university teaching hospital. All consecutive patients staying ≥4 days were enrolled. Potential risk factors were recorded: pathology, energy intake, amount and type of nutritional lipids, intake of propofol, glucose intake, laboratory parameters, and drugs. Triglyceride (TG) levels were assessed three times weekly. Statistics was based on two-way analysis of variance (ANOVA) and linear regression with potential risk factors.ResultsOut of 1,301 consecutive admissions, 220 patients were eligible, of whom 99 (45 %) presented hyperTG (triglycerides >2 mmol/L). HyperTG patients were younger, heavier, with more brain injury and multiple trauma. Intake of propofol (mg/kg/h) and lipids’ propofol had the highest correlation with plasma TG (r2 = 0.28 and 0.26, respectively, both p < 0.001). Infection and inflammation were associated with development of hyperTG [C-reactive protein (CRP), r2 = 0.19, p = 0.004]. No strong association could be found with nutritional lipids or other risk factors. Outcome was similar in normo- and hyperTG patients.ConclusionsHyperTG is frequent in the ICU but is not associated with adverse outcome. Propofol and accompanying lipid emulsion are the strongest risk factors. Our results suggest that plasma TG should be monitored at least twice weekly in patients on propofol. The clinical consequences of propofol-related hyperTG should be investigated in further studies. More... »

PAGES

1990-1998

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00134-012-2688-8

DOI

http://dx.doi.org/10.1007/s00134-012-2688-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1022652034

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23052949


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Critical Illness", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Carriers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fat Emulsions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertriglyceridemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypnotics and Sedatives", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Linear Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multivariate Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prevalence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Propofol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Switzerland", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Geneva, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.8591.5", 
          "name": [
            "Service of Pharmacy, Lausanne University Hospital, Lausanne, Switzerland", 
            "School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Geneva, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Devaud", 
        "givenName": "J.-C.", 
        "id": "sg:person.011467217702.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011467217702.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service of Adult Intensive Care Medicine and Burns, Lausanne University Hospital, 1011, Lausanne, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.8515.9", 
          "name": [
            "Service of Adult Intensive Care Medicine and Burns, Lausanne University Hospital, 1011, Lausanne, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berger", 
        "givenName": "M. M.", 
        "id": "sg:person.01160620574.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160620574.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Geneva, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.8591.5", 
          "name": [
            "Service of Pharmacy, Lausanne University Hospital, Lausanne, Switzerland", 
            "School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Geneva, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pannatier", 
        "givenName": "A.", 
        "id": "sg:person.01363176311.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363176311.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Institute of Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.9851.5", 
          "name": [
            "University Institute of Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marques-Vidal", 
        "givenName": "P.", 
        "id": "sg:person.01327015201.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327015201.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Physiology, University of Lausanne, Lausanne, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.9851.5", 
          "name": [
            "Department of Physiology, University of Lausanne, Lausanne, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tappy", 
        "givenName": "L.", 
        "id": "sg:person.01171031441.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171031441.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of General Internal Medicine Inselspital, Bern University Hospital, Bern, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.411656.1", 
          "name": [
            "Department of Ambulatory Care and Community Medicine, University of Lausanne, Lausanne, Switzerland", 
            "Department of General Internal Medicine Inselspital, Bern University Hospital, Bern, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rodondi", 
        "givenName": "N.", 
        "id": "sg:person.01333440205.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333440205.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service of Adult Intensive Care Medicine and Burns, Lausanne University Hospital, 1011, Lausanne, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.8515.9", 
          "name": [
            "Service of Adult Intensive Care Medicine and Burns, Lausanne University Hospital, 1011, Lausanne, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chiolero", 
        "givenName": "R.", 
        "id": "sg:person.01121362247.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121362247.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Geneva, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.8591.5", 
          "name": [
            "Service of Pharmacy, Lausanne University Hospital, Lausanne, Switzerland", 
            "School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Geneva, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Voirol", 
        "givenName": "P.", 
        "id": "sg:person.01014631541.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014631541.05"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00134-003-1905-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033001107", 
          "https://doi.org/10.1007/s00134-003-1905-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/cc11418", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027159890", 
          "https://doi.org/10.1186/cc11418"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2261-8-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037509187", 
          "https://doi.org/10.1186/1471-2261-8-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002018-200124060-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036367781", 
          "https://doi.org/10.2165/00002018-200124060-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-2-287-33475-7_13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1089649646", 
          "https://doi.org/10.1007/978-2-287-33475-7_13"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/cc7294", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019343565", 
          "https://doi.org/10.1186/cc7294"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/cc8177", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024329861", 
          "https://doi.org/10.1186/cc8177"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-09-28", 
    "datePublishedReg": "2012-09-28", 
    "description": "PurposeHypertriglyceridemia (hyperTG) is common among intensive care unit (ICU) patients, but knowledge about hyperTG risk factors is scarce. The present study aims to identify risk factors favoring its development in patients requiring prolonged ICU treatment.MethodsProspective observational study in the medicosurgical ICU of a university teaching hospital. All consecutive patients staying \u22654\u00a0days were enrolled. Potential risk factors were recorded: pathology, energy intake, amount and type of nutritional lipids, intake of propofol, glucose intake, laboratory parameters, and drugs. Triglyceride (TG) levels were assessed three times weekly. Statistics was based on two-way analysis of variance (ANOVA) and linear regression with potential risk factors.ResultsOut of 1,301 consecutive admissions, 220 patients were eligible, of whom 99 (45\u00a0%) presented hyperTG (triglycerides >2\u00a0mmol/L). HyperTG patients were younger, heavier, with more brain injury and multiple trauma. Intake of propofol (mg/kg/h) and lipids\u2019 propofol had the highest correlation with plasma TG (r2\u00a0=\u00a00.28 and 0.26, respectively, both p\u00a0<\u00a00.001). Infection and inflammation were associated with development of hyperTG [C-reactive protein (CRP), r2\u00a0=\u00a00.19, p\u00a0=\u00a00.004]. No strong association could be found with nutritional lipids or other risk factors. Outcome was similar in normo- and hyperTG patients.ConclusionsHyperTG is frequent in the ICU but is not associated with adverse outcome. Propofol and accompanying lipid emulsion are the strongest risk factors. Our results suggest that plasma TG should be monitored at least twice weekly in patients on propofol. The clinical consequences of propofol-related hyperTG should be investigated in further studies.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00134-012-2688-8", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1313639", 
        "issn": [
          "0342-4642", 
          "1432-1238"
        ], 
        "name": "Intensive Care Medicine", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "12", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "38"
      }
    ], 
    "keywords": [
      "potential risk factors", 
      "risk factors", 
      "plasma TG", 
      "intensive care unit patients", 
      "prolonged ICU treatment", 
      "more brain injury", 
      "care unit patients", 
      "MethodsProspective observational study", 
      "University Teaching Hospital", 
      "strong risk factor", 
      "nutritional lipids", 
      "potential side effects", 
      "ICU treatment", 
      "unit patients", 
      "critical illness", 
      "consecutive patients", 
      "laboratory parameters", 
      "triglyceride levels", 
      "adverse outcomes", 
      "propofol sedation", 
      "glucose intake", 
      "consecutive admissions", 
      "multiple trauma", 
      "brain injury", 
      "teaching hospital", 
      "observational study", 
      "clinical consequences", 
      "side effects", 
      "patients", 
      "propofol", 
      "lipid emulsion", 
      "energy intake", 
      "hyperTG", 
      "intake", 
      "strong association", 
      "ICU", 
      "Further studies", 
      "two-way analysis", 
      "present study", 
      "outcomes", 
      "lipids", 
      "linear regression", 
      "factors", 
      "ResultsOut", 
      "sedation", 
      "inflammation", 
      "admission", 
      "hospital", 
      "normo", 
      "injury", 
      "illness", 
      "infection", 
      "pathology", 
      "trauma", 
      "study", 
      "drugs", 
      "treatment", 
      "association", 
      "high correlation", 
      "days", 
      "regression", 
      "levels", 
      "development", 
      "correlation", 
      "Tg", 
      "effect", 
      "consequences", 
      "knowledge", 
      "types", 
      "time", 
      "analysis", 
      "variance", 
      "results", 
      "statistics", 
      "amount", 
      "parameters", 
      "emulsions"
    ], 
    "name": "Hypertriglyceridemia: a potential side effect of propofol sedation in critical illness", 
    "pagination": "1990-1998", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1022652034"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00134-012-2688-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23052949"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00134-012-2688-8", 
      "https://app.dimensions.ai/details/publication/pub.1022652034"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:56", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_559.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00134-012-2688-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00134-012-2688-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00134-012-2688-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00134-012-2688-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00134-012-2688-8'


 

This table displays all metadata directly associated to this object as RDF triples.

296 TRIPLES      21 PREDICATES      126 URIs      111 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00134-012-2688-8 schema:about N083d4802b42d45f8be4851e40f2e7798
2 N0b8a025f6bca47479fbb31b7269fd0bf
3 N13b39303420f41a7b36199561124f91e
4 N1d75d1ca594a470e9112bb878df1ab82
5 N4147b6d1fc6b4b3f8f3bb7cd9e835db0
6 N47cb789acdd745f8aae78692f8d4f675
7 N5675e7037b1a4b24a35e9557247fb643
8 N7469fb6e50e94fc8a9cc955e45a66455
9 N8844884c2059499ea3a2acaa969c2948
10 N9774aa7eeb964694a85741fd17d60de9
11 N97e9af275b784f4e87536708fe422c32
12 N9bcf290d60854af3abe512f737e40978
13 N9e43948c2d60494b8cfd5bd11e531af4
14 Na0c7d312480547ae8749046b4542a475
15 Nc2719324b7bb4497bc0c4fa592ea2ea4
16 Nf7fafccb18374256b4da4fac5f2b7529
17 Nfa5dc337719f48bab63934d6dd7a9b69
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author N692a855d169749fa81aadcf33872074f
21 schema:citation sg:pub.10.1007/978-2-287-33475-7_13
22 sg:pub.10.1007/s00134-003-1905-x
23 sg:pub.10.1186/1471-2261-8-6
24 sg:pub.10.1186/cc11418
25 sg:pub.10.1186/cc7294
26 sg:pub.10.1186/cc8177
27 sg:pub.10.2165/00002018-200124060-00003
28 schema:datePublished 2012-09-28
29 schema:datePublishedReg 2012-09-28
30 schema:description PurposeHypertriglyceridemia (hyperTG) is common among intensive care unit (ICU) patients, but knowledge about hyperTG risk factors is scarce. The present study aims to identify risk factors favoring its development in patients requiring prolonged ICU treatment.MethodsProspective observational study in the medicosurgical ICU of a university teaching hospital. All consecutive patients staying ≥4 days were enrolled. Potential risk factors were recorded: pathology, energy intake, amount and type of nutritional lipids, intake of propofol, glucose intake, laboratory parameters, and drugs. Triglyceride (TG) levels were assessed three times weekly. Statistics was based on two-way analysis of variance (ANOVA) and linear regression with potential risk factors.ResultsOut of 1,301 consecutive admissions, 220 patients were eligible, of whom 99 (45 %) presented hyperTG (triglycerides >2 mmol/L). HyperTG patients were younger, heavier, with more brain injury and multiple trauma. Intake of propofol (mg/kg/h) and lipids’ propofol had the highest correlation with plasma TG (r2 = 0.28 and 0.26, respectively, both p < 0.001). Infection and inflammation were associated with development of hyperTG [C-reactive protein (CRP), r2 = 0.19, p = 0.004]. No strong association could be found with nutritional lipids or other risk factors. Outcome was similar in normo- and hyperTG patients.ConclusionsHyperTG is frequent in the ICU but is not associated with adverse outcome. Propofol and accompanying lipid emulsion are the strongest risk factors. Our results suggest that plasma TG should be monitored at least twice weekly in patients on propofol. The clinical consequences of propofol-related hyperTG should be investigated in further studies.
31 schema:genre article
32 schema:isAccessibleForFree true
33 schema:isPartOf N6476754c14f94c2c986bcc48db193768
34 Nf7a643b1449445d18e95f256692ecfcb
35 sg:journal.1313639
36 schema:keywords Further studies
37 ICU
38 ICU treatment
39 MethodsProspective observational study
40 ResultsOut
41 Tg
42 University Teaching Hospital
43 admission
44 adverse outcomes
45 amount
46 analysis
47 association
48 brain injury
49 care unit patients
50 clinical consequences
51 consecutive admissions
52 consecutive patients
53 consequences
54 correlation
55 critical illness
56 days
57 development
58 drugs
59 effect
60 emulsions
61 energy intake
62 factors
63 glucose intake
64 high correlation
65 hospital
66 hyperTG
67 illness
68 infection
69 inflammation
70 injury
71 intake
72 intensive care unit patients
73 knowledge
74 laboratory parameters
75 levels
76 linear regression
77 lipid emulsion
78 lipids
79 more brain injury
80 multiple trauma
81 normo
82 nutritional lipids
83 observational study
84 outcomes
85 parameters
86 pathology
87 patients
88 plasma TG
89 potential risk factors
90 potential side effects
91 present study
92 prolonged ICU treatment
93 propofol
94 propofol sedation
95 regression
96 results
97 risk factors
98 sedation
99 side effects
100 statistics
101 strong association
102 strong risk factor
103 study
104 teaching hospital
105 time
106 trauma
107 treatment
108 triglyceride levels
109 two-way analysis
110 types
111 unit patients
112 variance
113 schema:name Hypertriglyceridemia: a potential side effect of propofol sedation in critical illness
114 schema:pagination 1990-1998
115 schema:productId N090a887fb1e54e56beed6b86455ac6de
116 N807de3a26b8048c6a8b9a23c38be562b
117 Ne90ad355a2c5408db0ddf223436b83aa
118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022652034
119 https://doi.org/10.1007/s00134-012-2688-8
120 schema:sdDatePublished 2022-09-02T15:56
121 schema:sdLicense https://scigraph.springernature.com/explorer/license/
122 schema:sdPublisher Nb2c36816b2814d5aa23daaf18530395d
123 schema:url https://doi.org/10.1007/s00134-012-2688-8
124 sgo:license sg:explorer/license/
125 sgo:sdDataset articles
126 rdf:type schema:ScholarlyArticle
127 N083d4802b42d45f8be4851e40f2e7798 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Propofol
129 rdf:type schema:DefinedTerm
130 N090a887fb1e54e56beed6b86455ac6de schema:name dimensions_id
131 schema:value pub.1022652034
132 rdf:type schema:PropertyValue
133 N0b8a025f6bca47479fbb31b7269fd0bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Switzerland
135 rdf:type schema:DefinedTerm
136 N13b39303420f41a7b36199561124f91e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Risk Factors
138 rdf:type schema:DefinedTerm
139 N1d75d1ca594a470e9112bb878df1ab82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Hypertriglyceridemia
141 rdf:type schema:DefinedTerm
142 N4147b6d1fc6b4b3f8f3bb7cd9e835db0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Prospective Studies
144 rdf:type schema:DefinedTerm
145 N47cb789acdd745f8aae78692f8d4f675 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Fat Emulsions, Intravenous
147 rdf:type schema:DefinedTerm
148 N4d2d13cbc697408ebd6fe77cacccc5dc rdf:first sg:person.01121362247.08
149 rdf:rest N85527d9a28f742b19221864612328034
150 N5675e7037b1a4b24a35e9557247fb643 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Male
152 rdf:type schema:DefinedTerm
153 N6476754c14f94c2c986bcc48db193768 schema:volumeNumber 38
154 rdf:type schema:PublicationVolume
155 N692a855d169749fa81aadcf33872074f rdf:first sg:person.011467217702.08
156 rdf:rest Nac9d4a3732a443c4bbb43df71302c64f
157 N7469fb6e50e94fc8a9cc955e45a66455 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Humans
159 rdf:type schema:DefinedTerm
160 N7ed400ba44d04b7a8922c8864d427615 rdf:first sg:person.01333440205.38
161 rdf:rest N4d2d13cbc697408ebd6fe77cacccc5dc
162 N807de3a26b8048c6a8b9a23c38be562b schema:name doi
163 schema:value 10.1007/s00134-012-2688-8
164 rdf:type schema:PropertyValue
165 N85527d9a28f742b19221864612328034 rdf:first sg:person.01014631541.05
166 rdf:rest rdf:nil
167 N8844884c2059499ea3a2acaa969c2948 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Hypnotics and Sedatives
169 rdf:type schema:DefinedTerm
170 N9774aa7eeb964694a85741fd17d60de9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Linear Models
172 rdf:type schema:DefinedTerm
173 N97e9af275b784f4e87536708fe422c32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Middle Aged
175 rdf:type schema:DefinedTerm
176 N9bcf290d60854af3abe512f737e40978 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Multivariate Analysis
178 rdf:type schema:DefinedTerm
179 N9e43948c2d60494b8cfd5bd11e531af4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Drug Carriers
181 rdf:type schema:DefinedTerm
182 Na0c7d312480547ae8749046b4542a475 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Prevalence
184 rdf:type schema:DefinedTerm
185 Nac9d4a3732a443c4bbb43df71302c64f rdf:first sg:person.01160620574.24
186 rdf:rest Nd87096f56d204ebb9faded18457bf34c
187 Nb2c36816b2814d5aa23daaf18530395d schema:name Springer Nature - SN SciGraph project
188 rdf:type schema:Organization
189 Nbd879c39dea144c4b8cb7031f6912a19 rdf:first sg:person.01171031441.29
190 rdf:rest N7ed400ba44d04b7a8922c8864d427615
191 Nc2719324b7bb4497bc0c4fa592ea2ea4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Aged
193 rdf:type schema:DefinedTerm
194 Nd87096f56d204ebb9faded18457bf34c rdf:first sg:person.01363176311.88
195 rdf:rest Nfc9c55485b114b989b0b68f5ddcc291f
196 Ne90ad355a2c5408db0ddf223436b83aa schema:name pubmed_id
197 schema:value 23052949
198 rdf:type schema:PropertyValue
199 Nf7a643b1449445d18e95f256692ecfcb schema:issueNumber 12
200 rdf:type schema:PublicationIssue
201 Nf7fafccb18374256b4da4fac5f2b7529 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Female
203 rdf:type schema:DefinedTerm
204 Nfa5dc337719f48bab63934d6dd7a9b69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Critical Illness
206 rdf:type schema:DefinedTerm
207 Nfc9c55485b114b989b0b68f5ddcc291f rdf:first sg:person.01327015201.01
208 rdf:rest Nbd879c39dea144c4b8cb7031f6912a19
209 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
210 schema:name Medical and Health Sciences
211 rdf:type schema:DefinedTerm
212 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
213 schema:name Clinical Sciences
214 rdf:type schema:DefinedTerm
215 sg:journal.1313639 schema:issn 0342-4642
216 1432-1238
217 schema:name Intensive Care Medicine
218 schema:publisher Springer Nature
219 rdf:type schema:Periodical
220 sg:person.01014631541.05 schema:affiliation grid-institutes:grid.8591.5
221 schema:familyName Voirol
222 schema:givenName P.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014631541.05
224 rdf:type schema:Person
225 sg:person.01121362247.08 schema:affiliation grid-institutes:grid.8515.9
226 schema:familyName Chiolero
227 schema:givenName R.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121362247.08
229 rdf:type schema:Person
230 sg:person.011467217702.08 schema:affiliation grid-institutes:grid.8591.5
231 schema:familyName Devaud
232 schema:givenName J.-C.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011467217702.08
234 rdf:type schema:Person
235 sg:person.01160620574.24 schema:affiliation grid-institutes:grid.8515.9
236 schema:familyName Berger
237 schema:givenName M. M.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160620574.24
239 rdf:type schema:Person
240 sg:person.01171031441.29 schema:affiliation grid-institutes:grid.9851.5
241 schema:familyName Tappy
242 schema:givenName L.
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171031441.29
244 rdf:type schema:Person
245 sg:person.01327015201.01 schema:affiliation grid-institutes:grid.9851.5
246 schema:familyName Marques-Vidal
247 schema:givenName P.
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327015201.01
249 rdf:type schema:Person
250 sg:person.01333440205.38 schema:affiliation grid-institutes:grid.411656.1
251 schema:familyName Rodondi
252 schema:givenName N.
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333440205.38
254 rdf:type schema:Person
255 sg:person.01363176311.88 schema:affiliation grid-institutes:grid.8591.5
256 schema:familyName Pannatier
257 schema:givenName A.
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363176311.88
259 rdf:type schema:Person
260 sg:pub.10.1007/978-2-287-33475-7_13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1089649646
261 https://doi.org/10.1007/978-2-287-33475-7_13
262 rdf:type schema:CreativeWork
263 sg:pub.10.1007/s00134-003-1905-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1033001107
264 https://doi.org/10.1007/s00134-003-1905-x
265 rdf:type schema:CreativeWork
266 sg:pub.10.1186/1471-2261-8-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037509187
267 https://doi.org/10.1186/1471-2261-8-6
268 rdf:type schema:CreativeWork
269 sg:pub.10.1186/cc11418 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027159890
270 https://doi.org/10.1186/cc11418
271 rdf:type schema:CreativeWork
272 sg:pub.10.1186/cc7294 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019343565
273 https://doi.org/10.1186/cc7294
274 rdf:type schema:CreativeWork
275 sg:pub.10.1186/cc8177 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024329861
276 https://doi.org/10.1186/cc8177
277 rdf:type schema:CreativeWork
278 sg:pub.10.2165/00002018-200124060-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036367781
279 https://doi.org/10.2165/00002018-200124060-00003
280 rdf:type schema:CreativeWork
281 grid-institutes:grid.411656.1 schema:alternateName Department of General Internal Medicine Inselspital, Bern University Hospital, Bern, Switzerland
282 schema:name Department of Ambulatory Care and Community Medicine, University of Lausanne, Lausanne, Switzerland
283 Department of General Internal Medicine Inselspital, Bern University Hospital, Bern, Switzerland
284 rdf:type schema:Organization
285 grid-institutes:grid.8515.9 schema:alternateName Service of Adult Intensive Care Medicine and Burns, Lausanne University Hospital, 1011, Lausanne, Switzerland
286 schema:name Service of Adult Intensive Care Medicine and Burns, Lausanne University Hospital, 1011, Lausanne, Switzerland
287 rdf:type schema:Organization
288 grid-institutes:grid.8591.5 schema:alternateName School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Geneva, Switzerland
289 schema:name School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Geneva, Switzerland
290 Service of Pharmacy, Lausanne University Hospital, Lausanne, Switzerland
291 rdf:type schema:Organization
292 grid-institutes:grid.9851.5 schema:alternateName Department of Physiology, University of Lausanne, Lausanne, Switzerland
293 University Institute of Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland
294 schema:name Department of Physiology, University of Lausanne, Lausanne, Switzerland
295 University Institute of Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland
296 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...